-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
GC376 sodium
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1416992-39-6.gif)
Category | SARS-CoV |
CAS | 1416992-39-6 |
Description | GC376 is a 3CLpro inhibitor which is previously reported to be active against the 3CLpro of multiple coronaviruses, including SARS-CoV, but with highest potency against FIPV in cell culture. GC376 inhibits the replication of viruses TGEV, FIPV and PTV with IC50 values of 0.15, 0.2 and 0.15 μM. |
Product Information
Synonyms | GC376 sodium; GC 376 sodium; GC-376 sodium; (2S)-1-hydroxy-2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate sodium |
Molecular Weight | 507.53 |
Molecular Formula | C21H30N3NaO8S |
Canonical SMILES | CC(C)CC(C(=O)NC(CC1CCNC1=O)C(O)S(=O)(=O)O)NC(=O)OCC2=CC=CC=C2.[Na+] |
InChI | InChI=1S/C21H31N3O8S.Na/c1-13(2)10-16(24-21(28)32-12-14-6-4-3-5-7-14)19(26)23-17(20(27)33(29,30)31)11-15-8-9-22-18(15)25;/h3-7,13,15-17,20,27H,8-12H2,1-2H3,(H,22,25)(H,23,26)(H,24,28)(H,29,30,31);/q;+1/t15?,16-,17-,20?;/m0./s1 |
InChIKey | BSPJDKCMFIPBAW-JPBGFCRCSA-N |
Purity | ≥98% (HPLC) |
Solubility | Soluble in DMSO. |
Appearance | Solid powder |
Storage | Store in a cool and dry place (or refer to the Certificate of Analysis). |
Complexity | 783 |
Exact Mass | 507.16513038 |
Target | SARS-CoV-2 |